2026 / 01

DOI: 10.24075/dc.2026.005
Copyright: © 2026 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

REVIEW

Current problems and future prospects of specific measles therapy

Zarubaev VV , Lavrentieva IN
About authors

Saint Petersburg Pasteur Research Institute of Epidemiology and Microbiology, Saint Petersburg, Russia

Correspondence should be addressed: Irina N Lavrentieva
Mira St., 14, St. Petersburg, 197101, Russia; ur.liam@rwal.ruetsap

About paper

Financing: supported by the Ministry of Health of the Russian Federation and devoted to Development of New Preventive and Therapeutic Drugs against Socially Significant Viral Diseases. UDC 578.2.213; State Registration Number 121030200272-6.

Author contribution: Zarubaev VV — literature review, preparation of the manuscript; Lavrentieva IN — preparation of the manuscript.

Received: 2026-01-19 Accepted: 2026-03-07 Published online: 2026-03-23
|
  1. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS; Measles Initiative. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet. 2007 Jan 20; 369(9557): 191– 200. DOI: 10.1016/S0140-6736(07)60107-X.
  2. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015 May 8; 348(6235): 694–9. DOI: 10.1126/science.aaa3662.
  3. Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol. 2009 Feb; 38(1): 192–205. DOI: 10.1093/ije/dyn224.
  4. Salama P, Assefa F, Talley L, Spiegel P, van Der Veen A, Gotway CA. Malnutrition, measles, mortality, and the humanitarian response during a famine in Ehiopia. JAMA. 2001 Aug 1; 286(5): 563–71. DOI: 10.1001/jama.286.5.563.
  5. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nat Rev Dis Primers. 2016 Jul 14; 2: 16049. DOI: 10.1038/nrdp.2016.49.
  6. Cox R, Plemper RK. The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Front Microbiol. 2015 May 12; 6: 459. DOI: 10.3389/fmicb.2015.00459.
  7. Allen IV, McQuaid S, Penalva R, Ludlow M, Duprex WP, Rima BK. Macrophages and Dendritic Cells Are the Predominant Cells Infected in Measles in Humans. mSphere. 2018 May 9; 3(3): e00570–17. DOI: 10.1128/mSphere.00570-17.
  8. Laksono BM, Grosserichter-Wagener C, de Vries RD, Langeveld SAG, Brem MD, van Dongen JJM, Katsikis PD, Koopmans MPG, van Zelm MC, de Swart RL. In Vitro Measles Virus Infection of Human Lymphocyte Subsets Demonstrates High Susceptibility and Permissiveness of both Naive and Memory B Cells. J Virol. 2018 Mar 28; 92(8): e00131–18. DOI: 10.1128/JVI.00131-18.
  9. Griffin DE, Lin WH, Pan CH. Measles virus, immune control, and persistence. FEMS Microbiol Rev. 2012 May; 36(3): 649–62. DOI: 10.1111/j.1574-6976.2012.00330.x.
  10. Laksono BM, Fortugno P, Nijmeijer BM, de Vries RD, Cordisco S, Kuiken T, Geijtenbeek TBH, Duprex WP, Brancati F, de Swart RL. Measles skin rash: Infection of lymphoid and myeloid cells in the dermis precedes viral dissemination to the epidermis. PLoS Pathog. 2020 Oct 8; 16(10): e1008253. DOI: 10.1371/journal. ppat.1008253.
  11. Devaux P, Hodge G, McChesney MB, Cattaneo R. Attenuation of V- or C-defective measles viruses: infection control by the inflammatory and interferon responses of rhesus monkeys. J Virol. 2008 Jun; 82(11): 5359–67. DOI: 10.1128/JVI.00169-08.
  12. Ryon JJ, Moss WJ, Monze M, Griffin DE. Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles. Clin Diagn Lab Immunol. 2002 Sep; 9(5): 994–1003. DOI: 10.1128/cdli.9.5.994-1003.2002.
  13. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004 May 1; 189 Suppl 1: S4–16. DOI: 10.1086/377712.
  14. Thompson KM, Odahowski CL. The Costs and Valuation of Health Impacts of Measles and Rubella Risk Management Policies. Risk Anal. 2016 Jul; 36(7): 1357–82. DOI: 10.1111/risa.12459.
  15. Lebon P, Gelot A, Zhang SY, Casanova JL, Hauw JJ. Measles Sclerosing Subacute PanEncephalitis (SSPE), an intriguing and ever-present disease: Data, assumptions and new perspectives. Rev Neurol (Paris). 2021 Nov; 177(9): 1059–1068. DOI: 10.1016/j. neurol.2021.02.387. Erratum in: Rev Neurol (Paris). 2022 Jun; 178(6): 634. DOI: 10.1016/j.neurol.2022.04.002.
  16. WHO EpiBrief. A report on the epidemiology of selected vaccine-preventable diseases in the European Region. 2021; 1:8. Available from URL: https://www.who.int/europe/publications/i/item/ WHO-EURO-2024-10248-50020-75273. (accessed: 12.01.2026).
  17. Measles and rubella strategic framework 2021–2030. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
  18. WHO EpiBrief. A report on the epidemiology of selected vaccine-preventable diseases in the European Region. 2021;1:8. Available from URL: https://www.who.int/europe/publications/i/item/ WHO-EURO-2024-10248-50020-75273. (accessed: 12.01.2026).
  19. WHO EpiData. Measles and rubella monthly update — WHO European Region —March 2022. Available from URL: https://www. who.int/europe/publications/m/item/epidata-3-2022(accessed: 12.01.2026). Measles and rubella strategic framework 2021– 2030. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
  20. Strebel PM, Papania MJ, Fiebelkorn AP & Halsey NA in Vaccines: Expert Consult 6th edn (eds Plotkin SA, Orenstein WA & Offit PA) 352–387 (Elsevier Saunders, 2012).
  21. Mawson AR. Pathogenesis of measles and the mechanism of vitamin A treatment. J Transl Med. 2025 May 26; 23(1): 587. DOI: 10.1186/s12967-025-06545-9.
  22. Lin LT, Chen TY, Lin SC, Chung CY, Lin TC, Wang GH, Andersn R, Lin CC, Richardson CD. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol. 2013 Aug 7; 13: 187. DOI: 10.1186/1471-2180-13-187.
  23. Fukuhara H, Mwaba MH, Maenaka K. Structural characteristics of measles virus entry. Curr Opin Virol. 2020 Apr; 41: 52–58. DOI: 10.1016/j.coviro.2020.04.002.
  24. Plattet P, Alves L, Herren M, Aguilar HC. Measles Virus Fusion Protein: Structure, Function and Inhibition. Viruses. 2016 Apr 21; 8(4): 112. DOI: 10.3390/v8040112.
  25. Richardson CD, Scheid A, Choppin PW. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. Virology. 1980 Aug; 105(1): 205–22. DOI: 10.1016/0042-6822(80)90168-3.
  26. Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B, Liotta DC, Snyder JP, Compans RW. A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci U S A. 2004 Apr 13; 101(15): 5628–33. DOI: 10.1073/pnas.0308520101.
  27. Plemper RK, Lakdawala AS, Gernert KM, Snyder JP, Compans RW. Structural features of paramyxovirus F protein required for fusion initiation. Biochemistry. 2003 Jun 10; 42(22): 6645–55. DOI: 10.1021/bi034385k.
  28. Plemper RK, Compans RW. Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation. J Virol. 2003 Apr; 77(7): 4181–90. DOI: 10.1128/jvi.77.7.4181-4190.2003.
  29. Plemper RK, Doyle J, Sun A, Prussia A, Cheng LT, Rota PA, Liotta DC, Snyder JP, Compans RW. Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother. 2005 Sep; 49(9): 3755–61. DOI: 10.1128/AAC.49.9.3755-3761.2005.
  30. Sun A, Prussia A, Zhan W, Murray EE, Doyle J, Cheng LT, Yoon JJ, Radchenko EV, Palyulin VA, Compans RW, Liotta DC, Plemper RK, Snyder JP. Nonpeptide inhibitors of measles virus entry. J Med Chem. 2006 Aug 24; 49(17): 5080–92. DOI: 10.1021/jm0602559.
  31. Doyle J, Prussia A, White LK, Sun A, Liotta DC, Snyder JP, Compans RW, Plemper RK. Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J Virol. 2006 Feb; 80(3): 1524–36. DOI: 10.1128/ JVI.80.3.1524-1536.2006.
  32. Prussia AJ, Plemper RK, Snyder JP. Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance. Biochemistry. 2008 Dec 23; 47(51): 13573–83. DOI: 10.1021/bi801513p.
  33. Ha MN, Delpeut S, Noyce RS, Sisson G, Black KM, Lin LT, Bilimoria D, Plemper RK, Privé GG, Richardson CD. Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide. J Virol. 2017 Nov 14; 91(23): e01026–17. DOI: 10.1128/JVI.01026-17.
  34. Moyer SA, Baker SC, Horikami SM. Host cell proteins required for measles virus reproduction. J Gen Virol. 1990 Apr; 71 (Pt 4): 775–83. DOI: 10.1099/0022-1317-71-4-775.
  35. Bose S, Banerjee AK. Beta-catenin associates with human parainfluenza virus type 3 ribonucleoprotein complex and activates transcription of viral genome RNA in vitro. Gene Expr. 2004; 11(5–6): 241–9. DOI: 10.3727/000000003783992252.
  36. Yoon JJ, Krumm SA, Ndungu JM, Hoffman V, Bankamp B, Rota PA, Sun A, Snyder JP, Plemper RK. Target analysis of the experimental measles therapeutic AS-136A. Antimicrob Agents Chemother. 2009 Sep; 53(9): 3860.
  37. White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK. Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother. 2007 Jul; 51(7): 2293–303. DOI: 10.1128/AAC.00289-07.
  38. Sun A, Chandrakumar N, Yoon JJ, Plemper RK, Snyder JP. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorg Med Chem Lett. 2007 Sep 15; 17(18): 5199– 203. DOI: 10.1016/j.bmcl.2007.06.084.
  39. Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, Sun A, Saindane MT, Arrendale RF, Painter G, Liotta DC, Natchus MG, von Messling V, Plemper RK. An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model. Sci Transl Med. 2014 Apr 16; 6(232): 232ra52. DOI: 10.1126/scitranslmed.3008517.
  40. Cox RM, Sourimant J, Govindarajan M, Natchus MG, Plemper RK. Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. PLoS Pathog. 2021 Feb 23; 17(2): e1009371. DOI: 10.1371/journal. ppat.1009371.
  41. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. 1994 Sep; 19(3): 454–62. DOI: 10.1093/clinids/19.3.454.
  42. Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 1989 May 5; 261(17): 2512–6.
  43. Hashimoto K, Maeda H, Miyazaki K, Watanabe M, Norito S, Maeda R, Kume Y, Ono T, Chishiki M, Suyama K, Sato M, Hosoya M. Antiviral Effect of Favipiravir (T-705) against Measles and Subacute Sclerosing Panencephalitis Viruses. Jpn J Infect Dis. 2021 Mar 24; 74(2): 154–156. DOI: 10.7883/yoken. JJID.2020.481.
  44. Chen Q, Liu C, Komazin G, Bowlin TL, Schneller SW. Synthesis and antiviral activities of 3-deaza-3-fluoroaristeromycin and its 5’ analogues. Bioorg Med Chem. 2014 Dec 15; 22(24): 6961–4. DOI: 10.1016/j.bmc.2014.10.014.
  45. Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, Rajappan VP, Schneller SW, Smee DF, Sidwell RW. Inhibition of measles virus replication by 5’-nor carbocyclic adenosine analogues. Antivir Chem Chemother. 2001 Jul; 12(4): 241–50. DOI: 10.1177/095632020101200405.
  46. Li W, Yin X, Schneller SW. 5’-Fluoro-5’-deoxyaristeromycin. Bioorg Med Chem Lett. 2008 Jan 1; 18(1): 220–2. DOI: 10.1016/j. bmcl.2007.10.095.
  47. Lieberherr C, Zhang G, Grafen A, Singethan K, Kendl S, Vogt V, Maier J, Bringmann G, Schneider-Schaulies J. The Plant-Derived Naphthoquinone Droserone Inhibits In Vitro Measles Virus Infection. Planta Med. 2017 Feb; 83(3–04): 232–238. DOI: 10.1055/s-0042-111825.
  48. Wachsman MB, Ramirez JA, Galagovsky LR, Coto CE. Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother. 2002 Jan; 13(1): 61–6. DOI: 10.1177/095632020201300105.
  49. Yan D, Krumm SA, Sun A, Steinhauer DA, Luo M, Moore ML, Plemper RK. Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response. J Virol. 2013 Oct; 87(20): 11076–87. DOI: 10.1128/JVI.01425-13.
  50. Sinopoli A, Caminada S, Isonne C, Santoro MM, Baccolini V. What Are the Effects of Vitamin A Oral Supplementation in the Prevention and Management of Viral Infections? A Systematic Review of Randomized Clinical Trials. Nutrients. 2022 Oct 1; 14(19): 4081. DOI: 10.3390/nu14194081.